VEGFA and wet macular degeneration: RC28E (RemeGen, Yantai Shandong, China) is a dual decoy receptor for VEGF and bFGF and was tested in Phase I/II clinical trial (NCT04270669) for wet AMD and Phase II clinical trials (NCT04782128, NCT04782115) for DR and DME.